Safety and PK of TAF/EVG Vaginal Insert

Phase 1, randomised, open-label trial of tenofovir alafenamide and elvitegravir in human immunodeficiency virus infection (HIV) and herpes simplex virus infection (2 arms), sponsored by CONRAD. Primary endpoints: Number of Participants with Grade 2 or higher treatment-emergent adverse events at 12 days, Number of participants with adverse events at 12 days and 2 more. Started Dec 2018; status: completed.